Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Pr... ( KING OF PRUSSIA Pa. Aug. 18 /- Em...)

HOME >> BIOLOGY >> TECHNOLOGY

Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target

Date:8/18/2008

KING OF PRUSSIA, Pa., Aug. 18 /PRNewswire/ -- Emerging Growth Equities, Ltd. initiates coverage of CombiMatrix Corporation (Nasdaq: CBMX) with a BUY rating and an $18.00 price target. CombiMatrix is a life sciences company focused on developing and commercializing in vitro genetic diagnostics that leverage its core CustomArray technology.

Emerging Growth Equities, Ltd., is a specialty brokerage and investment banking firm that provides high quality distribution, research and trade execution for institutional and retail clients. Emerging Growth Equities, Ltd. specializes in fulfilling the capital requirements of well-managed emerging growth companies.

Institutional investors may call their Emerging Growth Equities, Ltd. sales person for a full text of the report at 888-293-1800.

This publication is neither an offer to sell nor a solicitation to buy any securities mentioned herein. The information contained herein is based on data obtained from recognized sources that are believed to be reliable. Emerging Growth Equities, Ltd. has not independently verified the facts, assumptions and estimates contained in this report. Accordingly, no representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. The information contained in this report is not and does not purport to be a complete analysis of every material fact respecting any company, industry, or security.

Most of the companies Emerging Growth Equities, Ltd. follows are emerging and mid-sized growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more
'/>"/>

SOURCE Emerging Growth Equities, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
2. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
3. Pharsight to Present at Jesup and Lamont 2008 Emerging Growth Stock Conference
4. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
5. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
6. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
7. NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company
8. Project on Emerging Nanotechnologies and Consumers Union collaborate on ConsumersTalkNano
9. Luminex Corporation to Present at Americas Growth Capital Emerging Growth Conference
10. Neurocrine Biosciences to Present at the A.G. Edwards Annual Emerging Growth Conference
11. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference

Post Your Comments:

(Date:12/2/2009)JERUSALEM, Israel, December 2 Gamida Cell announced today,a feasibility study evaluating the preclinical (animal study) safety and,efficacy of a gene therapy product which combines technology from We

(Date:12/2/2009)NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: SCR ), a leading pharmaceutical company,specializing in the development, manufacturing, a

(Date:12/2/2009)The Scientist, a leading scientific magazine covering the life sciences, ranked Photometrics’ Evolve “Intelligent” EMCCD camera fourth among the publication’s “Top 10 Inn

(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with

Breaking Biology Technology:Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2 Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3 Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2 Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3 The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2 The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3 PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2 PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3

[0] Gamida Cell Announces Feasibility Study With Weill Cornell Medical College [0] Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List [0] The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 [0] PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million

...asdaq: TELK ) today announced top-line results fr...yta (canfosfamide HCL) in combination with,pegylat... second-line,therapy in platinum refractory, prima...ant ovarian cancer (definitions of platinum status...) basis for the 125 enrolled patients, the,median ...

...nces Cash Position -, HOPKINTON, Mass., Oct. 29 ...ading provider of tools and services for,drug disc...that it has,reached an agreement to sell its Pharm...duct line to SOTAX Corporation in a transaction va...ct line consists of products used,for drug content...

...me Per Share, SAN JOSE, Calif., Oct. 29 VNUS(R) ...ding provider of medical devices,for the minimally...nced its,financial results for the third quarter e...ird quarter of 2008 increased 32% to $23.1,million... of 2007. Net,revenues for the third quarter of 20...

Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer Caliper Enters Agreement to Divest Non-Core Pharmaceutical Development & Quality Analysis Product Line VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007

(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O

(Date:12/2/2009)PHILADELPHIA Less acculturated Latino men have a more difficult time quitting smoking than those who are more acculturated to U.S. culture, but acculturation has no affect on Latinas odds of quitting

(Date:12/2/2009)PHILADELPHIA Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient,s future risk of death, according to published studies. Now, results of a ne

Breaking Biology News(10 mins):CCNY professor foresees rising Antarctic snowmelt 2 Acculturation affects smoking cessation success among Latinos 2 Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2 59 percent support Massachusetts Landmark 2006 health reform law 58399 1 59 percent support Massachusetts Landmark 2006 health reform law 58399 2 59 percent support Massachusetts Landmark 2006 health reform law 58399 3 Excellence in Paediatrics conference line up includes WHO and CDC pandemic speakers 10130 1 Excellence in Paediatrics conference line up includes WHO and CDC pandemic speakers 10130 2 Getting down to details 10125 1 Getting down to details 10125 2

[0] CCNY professor foresees rising Antarctic snowmelt [0] Acculturation affects smoking cessation success among Latinos [0] Head and neck cancer survivors who use alcohol and cigarettes have increased death risk

..., Fla. Older, active people who have a drink or t...k, according to a report today from a University o...s on Alcohol and Drugs . , Although people 50 or ...how younger people did, they performed worse on sp...ol and did not always realize when they were impai...

...identified seven new species of bamboo coral disco...of the Papahānaumokuākea Marine National...rely new genera, a remarkable feat given the broad...ajor category in the classification of organisms, ...ists expect to identify more new species as analys...

... largest research project into children,s health a... as obesity, obesity-related diseases and learning...ed by Professor Arne Astrup, is based at LIFE - Fa... and will focus on a new eating concept, termed th...d products. , Overweight has been estimated to aff...

Other Biology News:After a few drinks, older adults more impaired than they think 2 After a few drinks, older adults more impaired than they think 3 New deep-sea coral discovered on NOAA-supported mission 2 Enhanced quality of 'LIFE' through Nordic food 2

After a few drinks, older adults more impaired than they think New deep-sea coral discovered on NOAA-supported mission Enhanced quality of 'LIFE' through Nordic food

DNA Polymerase I Large (Klenow) Fragment from New England Biolabs

T4 DNA Ligase (HC) from Invitrogen

Rat Anti-STENOTROPHOMONAS MALTOPHILIA Polyclonal Antibody, Unconjugated from AbD Serotec

... upgrade for Shimadzu Phoretix 2D, Expression and ...stical tools for comparative gel analysis studies ...Data base add on component Oracle data base plug...software). Supports advanced statistical tool se...

Biology Products:

DNA Polymerase I Large (Klenow) Fragment from New England Biolabs T4 DNA Ligase (HC) from Invitrogen Rat Anti-STENOTROPHOMONAS MALTOPHILIA Polyclonal Antibody, Unconjugated from AbD Serotec Shimadzu Phoretix Pro upgrade from Shimadzu Biotech

Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Pr...( KING OF PRUSSIA Pa. Aug. 18 /- Em...)